Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 10;9:287–298. doi: 10.2147/CMAR.S138932

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Zeng et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Network plot of induction treatments included in the NMA.

Notes: Circles represent the intervention as a node in the network, lines represent direct comparisons using RCTs, and the thickness of lines corresponds to the number of RCTs included in each comparison.

Abbreviations: Cy-Dex, cyclophosphamide plus dexamethasone; NMA, network meta-analysis; PAD, bortezomib plus doxorubicin plus dexamethasone; RCTs, randomized controlled trials RD, lenalidomide plus dexamethasone; TAD, thalidomide plus doxorubicin plus dexamethasone; TD, thalidomide plus dexamethasone; VAD, vincristine plus doxorubicin plus dexamethasone; VBMCP-VBAD-B, BCNU plus vincristine plus melphalan plus prednisone plus dexamethasone plus bortezomib; VD, bortezomib plus dexamethasone; VDC, bortezomib plus dexamethasone plus cyclophosphamide; VDCR, bortezomib plus dexamethasone plus cyclophosphamide plus lenalidomide; VDR, bortezomib plus dexamethasone plus lenalidomide; VTD, bortezomib plus thalidomide plus dexamethasone; VTDC, bortezomib plus thalidomide plus dexamethasone plus cyclophosphamide.